Home   Business   Article

Subscribe Now

Domainex expands bioanalytic chemistry services with £1m Waters investment



More news, no ads

LEARN MORE


Domainex, the integrated medicines research services partner based on Chesterford Research Park, has purchased more than £1m worth of new Waters equipment to expand its bioanalytical chemistry services.

Dr Ausra Jablonskyte using one of the new pieces of equipment from the £1m investment at Domainex. Picture: Keith Heppell
Dr Ausra Jablonskyte using one of the new pieces of equipment from the £1m investment at Domainex. Picture: Keith Heppell

Domainex is a leading, multi-award-winning, integrated medicines research service partner working with ambitious life science organizations from around the globe. Established in 2001, the company works collaboratively with pharmaceutical and biotechnology companies, patient foundations and leading academic institutions globally, providing innovative and customised biology and chemistry services to advance the disease research projects of its partners, from target expression to pre-clinical development candidate nomination.

Included in the new equipment are two ACQUITY UPLC systems, one with an evaporative light scattering detector (ELSD) and one with a single quadrupole (SQ) detector, three mass-directed auto purification systems (one with an SQ detector), and a highly sensitive Xevo TQ-XS triple quadrupole mass spectrometer.

The Xevo TQ-XS will allow Domainex to expand its range of in vitro ADME (absorbance, distribution, metabolism and excretion) services to include hepatocyte stability assessments and permeability studies. To provide a continuous supply of high-quality nitrogen to the Xevo TQ-XS, Domainex has also purchased a new HF30A Chromalytic generator.

Domainex Tom Mander, CEO, and Jon Powell, project manager, in one of the Domainex labs at Chesterford Research Park. Picture: Keith Heppell
Domainex Tom Mander, CEO, and Jon Powell, project manager, in one of the Domainex labs at Chesterford Research Park. Picture: Keith Heppell

The recent investment complements the existing suite of Waters analytical instrumentation already in use at Domainex. It will allow the company to increase its capacity and throughput, enhance its capabilities in analytical chemistry, bioanalytical sciences and in vitro ADME assays, and thereby support its ongoing growth.

The purchase follows a recent expansion for Domainex, including the opening of a new facility at Unity Campus in Pampisford.

Dr Tom Mander, Domainex’s CEO, said: “We have an ambitious capital investment programme planned for 2022 which we are funding from our profits. We are seeing strong demand for our range of bioanalytical chemistry services.

“This significant capital investment will give our analytical chemistry team access to state-of-the-art technologies to provide high-quality data to our clients. This expansion will allow us to continue to fully support our integrated drug discovery programmes. We have used Waters equipment for many years and have always been pleased with the quality of their products and the first-class support they provide us.”

Joe Kildunne, director for pharmaceutical marketing at Waters, added: “It is a pleasure to partner with Domainex, an organisation who understand the need to provide best in class scientific solutions for their sponsors. At Waters we are passionate about providing our customers with the tools and support they need to grow their scientific capabilities and their business success.’’



This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More